Neuralzeta Efficacy & Side Effects

---

From patient data collected through 2017, we do know:

• Neuralzeta is effective in 84% of PALS treated, with a noticeable slowing in the patients rate of decline.   

• 52% of patients treated with Neuralzeta stabilize for more than four months. 

• 26% of patients treated with Neuralzeta stabilize for more than one year.  

• 4% of patients treated with Neuralzeta have ALSFRS-R scores that actually improve.  

For some PALS, the drug halts the decline of their ALSFRS-R score over time. Fewer PALS note the improvement, or reversal, of their ALSFRS-R score over time, but these results usually take much longer.

The cases of score reversal (improvement of the condition) may raise a question about the accuracy of their diagnosis. In case of the error in diagnosis, they can observe the efficacy of the drug applied to other neurodegenerative conditions. The patients themselves admit that as long as the treatment improves their function or slows down their decline, the name of their disease is irrelevant to them.

Unlike in trials, there is no inclusion or exclusion criteria for PALS who desire to take Neuralzeta. The charity provides it on a humanitarian basis, which distinguishes their efforts from clinical trials.  In clinical trials, there are inclusion/exclusion requirements that also include a percentage of participants to use a placebo. 

PALS are taken on a first come first serve basis by simply filling out a form on the charities website. This avoids skewing of the statistical analysis in favor of the efficacy of the drug, unlike clinical trials where patients are carefully selected for best outcome. The charity has no placebo control group, and all of PALS receive the actual Neuralzeta drug.